Research Output per year
Professor Graeme J Hankey, MBBS, MD, FRCP, FRCPEdin, FRACP, FAHA, FESO, FAAHMS, FWSO is Professor of Neurology, Medical School, Faculty of Health and Medical Sciences, The University of Western Australia; Consultant Neurologist, Sir Charles Gairdner Hospital; Clinical Trials Advisor, the Harry Perkins Institute of Medical Research; and Research Affiliate, the Perron Institute for Neurological and Translational Science, Western Australia.
He received his undergraduate medical training at the University of Western Australia, and trained in neurology at the Royal Perth Hospital, Australia; Mayo Clinic, USA; and Western General Hospital, Edinburgh, UK.
Roles and responsibilities
He was associate editor (editor for Asia Pacific submissions) of Stroke from 2000-2010; associate editor of Stroke Treatment and Prevention from 2009-2016; and member of the editorial board of Practical Neurology from 2000-2015.
Professor Hankey is presently co-principal investigator of the Assessment oF FluoxetINe In sTroke RecoverY (AFFINITY) trial in Australia, New Zealand and Vietnam; Steering committee member of the Efficacy of Fluoxetine- a randomised controlled trial in stroke (EFFECTS) in Sweden, the AXIOMATIC phase 2 trial of an oral factor XIa inhibitor in addition to clopidogrel and aspirin in preventing recurrent stroke among patients with acute TIA and mild ischaemic stroke, the Reducing the International Burden of Stroke Using Mobile Technology (RIBURST) and Stroke Riskometer app Study, and the planned Polypill and RiskOMeter to prevent strOke and cogniTive impairment (PROMOTE) trial; and a principal investigator of the Health In Men Study (HIMS). He is a member of the Global Burden of Disease Stroke Expert Panel. He is the chair of two, and a member of seven, data safety monitoring committees of ongoing clinical trials.
Professor Hankey and his colleagues have been awarded $72 million in competitive research grants, including $9.5 million from international grants and $62 million from national grants ($58.7 million NHMRC, $4 million other).
His current grants as a chief investigator include an NHMRC project grant, NHRMC program grant, and NHMRC Practitioner Fellowship as outlined below:
Hankey GJ, Hackett M, Almeida O, Flicker L, Mead G, Dennis MS, Etherton-Beer C, Ford A, Billot L, Jan S.
Assessment oF FluoxetINe In sTroke recoverY (AFFINITY)
NHMRC Project Grant, Application: APP1059094
$2,212,237.40 for 2014-2019
Davis SM, Donnan GA, Hankey GJ, Parsons M, Levi C, Campbell B
Saving brain and changing practice in stroke.
NHMRC Program Grant, Application ID: 1113352.
$ 13,787,375.00 for 5 years (2017-2021).
The NHMRC program grant for 2017-2021 was the top ranked NHMRC Program Grant application for the year.
Reducing the burden of stroke
NHMRC Practitioner Fellowship, Application ID: APP1137020
$577,188.50 for 5 years, 2018-2022
Additional current funding include:
Mead G, Dennis M, House A, Forbes J, MacLeod M, Lewis S, Hankey G, Hackett M, Anderson C, Morales D, Sullivan F.
Fluoxetine of control Under Supervision (FOCUS). A multicentre randomised trial to establish the effect(s) or routine administration of Fluoxetine in patients with a recent stroke.
United Kingdom National Institute for Health Research Technology (NIHR) Health Technology Assessment Programme (HTA), HTA Project 13/04/30
UK £ 2,088,148 for 54 months; October 1, 2014 - March 31, 2019
Murray V, Norvving B, Wester P, Dennis M, Mead G, Hankey G, Hackett M, Mårtensson B, Castrén E, Wallén H, Lundström E. EFFECTS – a Swedish multicentre randomised placebo-controlled trial to establish the efficacy of fluoxetine in patients with a recent stroke.
Vetenskapsrådet (The Swedish Research Council), 921-2014-7072
SEK (Swedish Krona) 31,114,000 = Aus $ 5 million
January 1, 2015 to 31 December 2019
Godecke E, Armstrong E, Bernhardt J, Middleton S, Rai T, Holland A, Cadilhac D, Hankey GJ, Whitworth A, Rose M, Ciccone N.
Very Early Rehabilitation in SpEech (VERSE): An RCT of aphasia therapy after stroke.
The Tavistock Trust for Aphasia, United Kingdom. 2017-2018; £75,000.00. (AUD$122,000.00) Philanthropic funding.
Flicker L, et al
Hankey GJ (AI)
Reaching the tenth decade of life in Australia – A 20-year longitudinal study of older men
NHMRC Project Grant, APP1128083
$890,062.80 for 5 years, 2017-21
Laing N, et al
Hankey GJ (AI)
Identifying disease genes for neurogenetic disorders using next generation sequencing
NHMRC Project Grant, APP1080587
$ 2,416,717.50 for five years, 2015-2019
Armstrong E, et al.
Hankey GJ (AI)
Enhancing rehabilitation services for Aboriginal Australians after brain injury.
NHMRC Partnership Projects, APP1132468
$ 906,444.60 for 5 years, 2016-2020
1988. Senior Clinical Fellow in Neurology, Mayo Clinic, Rochester, Minnesota, USA
1989-1992. Research Fellow, Dept. of Clinical Neurosciences, University of Edinburgh,
Western General Hospital, Edinburgh, Scotland, UK (Supervisor Prof. CP Warlow)
1992-2013. Consultant Neurologist, RPH
1998-2013, Head of Stroke Unit,RPH
The Health in Men Study (HIMS).
Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial: An Australasian, multi-centre, randomized, double-blind, placebo-controlled trial of the efficacy of fluoxetine in improving functional recovery after acute stroke.
Efficacy of Fluoxetine- a randomised controlled trial in stroke (EFFECTS) in Sweden.
AXIOMATIC, a global, phase 2 trial of adding an oral factor XIa inhibitor to clopidogrel and aspirin to prevent recurrent stroke in patients with acute TIA and mild ischaemic stroke.
The Longitudinal Study of Young Adults with Embolic Stroke of Undetermined Source.
The Reducing the International Burden of Stroke Using Mobile Technology (RIBURST) and Stroke Riskometer app Study.
The Global Burden of Disease Study
Polypill and RiskOMeter to prevent strOke and cogniTive impairment (PROMOTE) trial
Professor Hankey has delivered > 565 invited lectures at international (n=335), national (n=131), and local (n=100) scientific meetings.
He also regularly teaches and examines undergraduate medical students and postgraduate medical, nursing and allied health colleagues.
Professor Hankey's main research interests include epidemiological studies and clinical trials of treatment strategies for acute stroke and stroke prevention.
He was the-
-Principal investigator of the international VITAmins To Prevent Stroke [VITATOPS] trial;
-Steering committee member of the international CHARISMA, AMADEUS, BOREALIS, ROCKET-AF and NAVIGATE-ESUS trials;
-Australian national coordinator of the international IST, SPIRIT, ESPRIT, FOOD, IST-3 and NAVIGATE-ESUS trials;
-Co-principal investigator of the Perth Community Stroke Study (PCSS) and Australian Co-operative Research on Subarachnoid Haemorrhage (ACROSS) studies;
-A chief investigator of the Health in Men Study (HIMS); and
-Member of the Stroke Unit Trialists' Collaboration, Antithrombotic Trialists' Collaboration, and INTERSTROKE study group.
Professor Hankey has authored or co-authored > 870 publications, including 11 books, 592 original articles, 100 review articles, 66 editorials, 39 commentaries, 32 case reports and 34 letters to the editor.
His most recent books are:
- Warlow's Stroke: Practical Management, Edited by Hankey GJ, Macleod M, Gorelick PB, Chen C, Caprio F, Mattle H. Wiley Blackwell, 4th Edition, 2019 (1008 pages; ISBN 978 1 118 49222 2); and
- Hankey's Clinical Neurology, Edited by Gorelick PB, Testai F, Hankey GJ, Wardlaw JM. Manson Publishing, London, and CRC Press, 2014 (975 pages, ISBN: 978 1 84076 193 1).
His publications have yielded
- >144,000 citations (h index 138) according to Google Scholar and
- >80,000 citations (h index 116) according to the Web of Science, Publons.
In 2017 and 2018, Professor Hankey was named a Highly Cited Researcher by the Web of Science Group, Clarivate Analytics for ranking in the top 1% of researchers in the world in the field of Clinical Medicine for the production of multiple highly cited papers that rank in the top 1% by citations for field and year.
In 2019, Professor Hankey was named a Higher Cited Researcher by the Web of Science Group, Clarivate Analytics, in recognition of exceptional performance demonstrated by production of multiple highly cited papers that rank in the top 1% in the world for field and year in Cross-Field.
The impact of Professor Hankey’s research on clinical practice and guidelines includes his roles as/in the:
Treatments for acute stroke
• Writing committee of the Stroke Unit Trialists’s Collaboration which established the role of organised stroke care in a multidisciplinary stroke unit (Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD000197);
• Steering Committee of the Australian Streptokinase Trial (JAMA 1996; 276: 961-6) and only randomised trial of intra-arterial thromboytic therapy in acute posterior circulation ischaemic stroke (Cerebrovasc Dis 2005; 20: 12-17), and national Australian coordinator of the International Stroke Trial-3 (Lancet 2012; 379: 2352-63) which contributed to establishing the role of thrombolysis for acute ischaemic stroke;
• Australian coordinator of the International Stroke Trial in 19,485 patients with acute ischaemic stroke, which established the role of aspirin as the initial treatment in acute ischaemic stroke to prevent early recurrent stroke (Lancet 1997; 349: 1569-81);
• Data Safety and Monitoring Committee of the Intensive Blood Pressure Reduction for Acute Cerebral Haemorrhage Trial (INTERACT) trial which established the role of blood pressure-lowering in acute haemorrhagic stroke (Lancet Neurology 2008; 7: 391-9; N Engl J Med. 2013; 368: 2355-65);
• Australian coordinator of the Feed Or Ordinary Diet (FOOD) trial which did not support a policy of routine oral supplementation after stroke (Lancet 2005; 365: 764-72) or early initiation of PEG feeding in dysphagic stroke patients (Lancet 2005; 365: 755-63);
• Co-principal investigator of one of the first randomized controlled trials of a behavioural intervention for dysphagia after acute stroke which showed a consistent trend towards more favourable outcomes in patients assigned a standard programme of early behavioural swallowing intervention (Lancet Neurology 2006; 5: 31-37);
Writing committee of the Fluoxetine Or Control Under Supervision (FOCUS) trial of fluoxetine vs placebo for 6 months in 3127 patients with recent stroke which showed that fluoxetine 20 mg given once daily for 6 months after acute stroke did not improve functional outcomes (Lancet Dec 5, 2018)
Anticoagulation for the prevention of cardioembolic ischemic stroke
• Executive Steering committee of the ROCKET‐AF trial which established the role of rivaroxaban as an alternative anticoagulant to warfarin in preventing stroke among 14,264 patients with atrial fibrillation (N Engl J Med 2011; 365: 883-91);
• Outcome event adjudication committee of the RE-LY trial which established the efficacy of dabagatran etexilate compared with warfarin in patients with atrial fibrillation (N Engl J Med. 2009; 361: 1139-51).
• Outcome event adjudication committee of the AVERROES trial which established the efficacy and safety of apixaban vs acetylsalicylic acid for preventing stroke in atrial fibrillation patients who have failed or are unsuitable for Vitamin K antagonist treatment (N Engl J Med. 2011; 364: 806-17.)
• Steering Committee of the AMADEUS trial which showed that long-term treatment with idraparinux was no worse than vitamin K antagonists in terms of efficacy, but caused significantly more bleeding, in 4,576 patients with atrial fibrillation at risk for thromboembolism [Lancet 2008; 371: 315-321).
• Steering Committee of the BOREALIS-AF trial (EFC10295) of subcutaneous biotinylated idraparinux (SSR126517E) with adjusted-dose warfarin in 3,773 patients with atrial fibrillation (J Thromb Haemost. 2014; 12: 824-30);
• Stroke Advisory & Adjudication Committee of the ACTIVE trials which showed that clopidogrel plus aspirin was not as effective as oral anticoagulation (Lancet 2006; 367: 1903-12.) but was more effective than aspirin for preventing stroke in patients with atrial fibrillation (N Engl J Med 2009; 360: 2066-78);
Antiplatelet therapy for the prevention of arterial ischemic stroke
• Antiplatelet and Antithrombotic Trialists’ Collaboration member, which confirmed the effectiveness of antiplatelet therapies for preventing recurrent vascular events in high vascular risk patients, including those with ischaemic stroke and TIA (BMJ 1994; 308: 81-106, BMJ 2002; 324: 71-86);
• Steering Committee and Australian coordinator of the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) which established the superiority of the combination of aspirin and extended-release dipyridamole compared to aspirin in 2,739 patients with ischaemic stroke of arterial origin (Lancet 2006; 367: 1665-73), and that anticoagulation is not as effective as antiplatelet therapy for ischaemic stroke of arterial origin (Lancet Neurol 2007; 6: 115-24);
• Investigator in the CAPRIE trial which established the superiority of clopidogrel compared to aspirin in preventing recurrent vascular events among patients with ischaemic stroke of arterial origin (Lancet 1996; 348: 1333-8);
• Steering Committee of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial which showed that long-term clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of major vascular events in 15,603 patients with symptomatic atherothrombosis and patients with multiple risk factors [N Engl J Med 2006; 354: 1706-17);
• Steering Committee of the Aortic arch Related Cerebral Hazard (ARCH) trial which reported that patients with an ischemic stroke and aortic arch plaques ≥4 mm treated with clopidogrel plus aspirin had a significant reduction in vascular death compared with patients allocated warfarin (Stroke 2014; 45:1248-57).
• Australian coordinator for the Stroke Prevention in Reversible Ischaemia Trial (SPIRIT), which established that anticoagulantion with an INR range of 3.0 to 4.5 in patients after cerebral ischemia of presumed arterial origin is not safe (Ann Neurol 1997, 42: 857-865),
• Steering Committee and Australian coordinator for Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P – TIMI 50) trial which showed that inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy but it increased the risk of moderate or severe bleeding (N Engl J Med. 2012; 366: 1404-13; Stroke. 2013; 44: 691-8).
• Steering Committee and Australian coordinator of the NAVIGATE ESUS trial which showed that rivaroxaban 15 mg once daily was not more effective than aspirin 100 mg once daily for preventing recurrent stroke in 7213 patients with recent Embolic Stroke of Undetermined Source (ESUS). N Engl J Med. 2018; 378: 2191-2201).
Lipid-lowering therapy for the prevention of arterial ischemic stroke
• Stroke Outcome Events Adjudication Committee of the Long‐term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial which contributed to establishing the role of cholesterol‐lowering by statins to prevent stroke (N Engl J Med 2000; 343: 317-326);
Carotid revascularisation for the prevention of arterial ischemic stroke
• Investigator in the ESCT and NASCET trials which established the role of carotid endarterectomy in the prevention of stroke among patients with recent carotid territory ischaemia due to severe ipsilateral carotid artery stenosis (Lancet 1998; 351: 1379-1387; N Engl J Med 1998; 339: 1415-25);
• Investigator in the CAVATAS trial which contributed to establishing the role of carotid artery stenting in the prevention of stroke among patients with recent carotid territory ischaemia due to severe ipsilateral carotid artery stenosis (Lancet 2001; 357: 1729-1737);
B-vitamins for the prevention of recurrent stroke
• Principal investigator of the VITAmins TO Prevent Stroke (VITATOPS) trial which showed that daily administration of folic acid, vitamin B6, and vitamin B12 to 8,164 patients with recent stroke or transient ischaemic attack was safe but not more effective than placebo in reducing the incidence of major vascular events (Lancet Neurology 2010; 9: 855-65);
Epidemiology of stroke
• Co-principal investigator of the Perth Community Stroke Study (PCSS) which was the first large community based study of the incidence and outcome of stroke in Australia, and the first to show that the incidence of stroke in the community of Perth, Australia declined by 40% between 1990 and 2000 (Stroke 2008; 39: 776-82);
• Co-principal investigator of the Australian Co-operative Research on Subarachnoid Haemorrhage (ACROSS) study which was the first large community based study of the incidence, triggers and outcome of subarachnoid haemorrhage in Australia (Stroke 2003; 34: 1771-1776);
• Co-principal investigator of the Health in Men Study (HIMS) which is one of the large cohorts studies of the incidence and predictors of multiple health outcomes, including stroke, among elderly Australian men (Int J Epidemiol 2009; 38: 48-52; Stroke. 2011; 42: 952-9)
• National Australian coordinator of the INTERSTROKE study which showed that ten risk factors are associated with 90% of the risk of stroke, suggesting that targeted interventions that reduce blood pressure and smoking, and promote physical activity and a healthy diet, could substantially reduce the global burden of stroke (Lancet 2010; 376: 112-23; Lancet 2016; 388: 761-75.; Lancet 2018; 391: 2019-2027)
• Co-author of the Hankey score for predicting future vascular events among patients with transient ischaemic attacks (JNNP 1992; 56: 752-9; BMJ 1993; 306: 1107-11; Stroke 2010; 41: 487-493; http://www.dcn.ed.ac.uk/model/predict.htm).
• Co-author of description of lacunar transient ischaemic attacks (Lancet 1991; 337: 335-8).
• Member of the Global Burden of Disease Stroke Expert Panel which has quantified the global disease burden due to neurological disorders in 2015 and its relationship with country development level (Lancet Neurology. 2017;16: 877-897); and described global, regional, and national: age-sex specific mortality for 264 causes of death, 1980-2016 (Lancet. 2017; 390: 1151-1210); incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016 (Lancet. 2017; 390:1211-1259); disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016 (Lancet. 2017; 390: 1260-1344); and comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks, 1990-2016 (Lancet. 2017; 390:1345-1422).
- Neuroscience: stroke
Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men (vol 103, pg 4224, 2018)Lamb, L. S., Alfonso, H., Norman, P. E., Davis, T. M. E., Forbes, J., Muench, G., Irrgang, F., Almeida, O. P., Golledge, J., Hankey, G. J., Flicker, L. & Yeap, B. B., Jan 2019, In : Journal of Clinical Endocrinology & Metabolism. 104, 1, p. 38-38 1 p.
Research output: Contribution to journal › Comment/debate
Associations of plasma IGF1, IGFBP3 and estradiol with leucocyte telomere length, a marker of biological age, in menYeap, B. B., Hui, J., Knuiman, M., Chubb, S. A., Ho, K. K. Y., Flicker, L., Divitini, M. L., Arscott, G. M., Twigg, S., Almeida, O., Hankey, G., Golledge, J. & Beilby, J., 1 Oct 2019, In : European Journal of Endocrinology.
Research output: Contribution to journal › Article
Research output: Contribution to journal › Article
Research output: Contribution to journal › Article
Projects per year
Hankey, G., Davis, S., Donnan, G., Parsons, M., Levi, C. & Campbell, B.
1/01/17 → 31/12/21